Dr. Louis DeGennaro helped advance 70% of the 110 blood cancer treatments approved by the FDA in the last six years – The Leukemia & Lymphoma Society
As LLS President & CEO Dr. Louis DeGennaro officially retires on 7/1, we reflect on the incredible progress LLS has made under his 18 years of leadership. ❤️ During his tenure, together we have:
🚀 Launched the ground-breaking Beat AML® Master Clinical Trial
🚀 Established the first-of-its-kind global master clinical trial for pediatric acute leukemia (PedAL)
🚀 Helped advance 70% of the 110 blood cancer treatments approved by the FDA in the last six years
🚀 Developed the pioneering Therapy Acceleration Program (TAP) to change the standard of blood cancer care
🚀 Created the Office of Public Policy to secure some of the most significant health policy reforms in history
And the progress continues! We are on the cusp of more transformative advancements under the leadership of LLS’s new President and CEO, E. Anders Kolb, MD.
Please share a warm wish or a fond memory of “Dr. Lou” as we wish him all the best on this next chapter of life. 👇 We’ll be forever grateful for his legacy, vision, and unwavering commitment to a world without blood cancer. ❤️